Q1 Earnings Estimate for XOMA Issued By Leerink Partnrs

XOMA Co. (NASDAQ:XOMA) – Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for XOMA in a research note issued on Tuesday, March 18th. Leerink Partnrs analyst D. Risinger anticipates that the biotechnology company will earn ($0.31) per share for the quarter. The consensus estimate for XOMA’s current full-year earnings is ($1.41) per share. Leerink Partnrs also issued estimates for XOMA’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.00 EPS and FY2029 earnings at $8.86 EPS.

Several other equities analysts also recently weighed in on XOMA. HC Wainwright dropped their target price on XOMA from $123.00 to $104.00 and set a “buy” rating for the company in a research report on Monday, February 3rd. StockNews.com downgraded shares of XOMA from a “hold” rating to a “sell” rating in a research note on Tuesday, February 25th.

XOMA Trading Up 0.8 %

Shares of NASDAQ XOMA opened at $20.89 on Wednesday. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $246.15 million, a PE ratio of -6.00 and a beta of 1.00. XOMA has a twelve month low of $19.92 and a twelve month high of $35.00. The stock has a fifty day simple moving average of $24.64 and a 200-day simple moving average of $27.29.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.17). The company had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%.

Insider Activity

In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of XOMA stock in a transaction on Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA

Institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets raised its position in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 795 shares in the last quarter. New York State Common Retirement Fund increased its stake in XOMA by 51.2% in the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 800 shares during the last quarter. Wells Fargo & Company MN raised its holdings in XOMA by 38.0% during the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 1,183 shares in the last quarter. Bank of America Corp DE raised its holdings in XOMA by 34.7% during the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock worth $205,000 after purchasing an additional 2,009 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in shares of XOMA in the 4th quarter valued at $206,000. 95.92% of the stock is owned by hedge funds and other institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.